Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
30°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Annovis Bio Inc.
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
March 27, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
March 25, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
March 21, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
March 11, 2025
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces New Publication in a Peer-Reviewed Journal
May 21, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
May 13, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
May 09, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
May 06, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
April 29, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
April 02, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Tickers
ANVS
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
April 01, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
March 20, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
February 27, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
February 14, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
January 30, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
January 24, 2024
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio to Participate in the 139th Yale CEO Summit
December 11, 2023
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
December 05, 2023
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Appoints Andrew Walsh as Vice President Finance
December 01, 2023
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
November 27, 2023
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023
From
Annovis Bio Inc.
Via
GlobeNewswire
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
October 12, 2023
From
Annovis Bio Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.